Brilinta DaYu Study

NCT01870921 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2004

Last updated 2018-04-03

Study results available
· View outcomes & findings →

Summary

A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the incidence of major cardiovascular events of ticagrelor in Chinese patients with acute coronary syndrome

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Ticagrelor

90mg/tablet, 1 tablet bid

Sponsors & Collaborators

Principal Investigators

  • Runlin Gao, Doctor · Fu Wai Hospital, Beijing, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-26
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01870921 on ClinicalTrials.gov